Drug Trial Radar · NCT02104947
Reversal of Dabigatran Anticoagulant Effect With Idarucizumab
Last checked: Nov 20, 2026Latest source record: Jan 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
503
Actual
Start
May 6, 2014
Primary completion
Jul 25, 2016
Study completion Oct 20, 2016
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Apr 7, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the reversal of the anticoagulant effects of dabigatran by IV administration of 5.0g idarucizumab in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.
Conditions
- Hemorrhage
Interventions
idarucizumabDrug
idarucizumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of dTT or ECTTime frame: from the end of the first infusion up to 4 hours after the last infusion on Day 1
Locations
176 sites in 33 countries. Site status is shown where the registry gives one.
Baptist Health Center for Clinical Research
Little Rock, Arkansas
Loma Linda University Medical Center
Loma Linda, California
MedStar Washington Hospital Center
Washington D.C., District of Columbia
University of Florida College of Medicine
Gainesville, Florida
Baptist Medical Center
Jacksonville, Florida
Mayo Clinic Cancer Center
Jacksonville, Florida
Tampa General Hospital
Tampa, Florida
St. Joseph's Hospital
Tampa, Florida
Northwestern University
Chicago, Illinois
OSF Saint Francis Medical Center
Peoria, Illinois
IU Health Methodist Hospital
Indianapolis, Indiana
Community Hospital
Munster, Indiana
Our Lady of the Lake Regional Medical Center
Baton Rouge, Louisiana
Newton-Wellesley Hospital
Newton, Massachusetts
Genesys Regional Medical Center
Grand Blanc, Michigan
Henry Ford Allegiance Health
Jackson, Michigan
Mercy Hospital St. Louis
St Louis, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
Duke University Medical Center
Durham, North Carolina
University of Cincinnati
Cincinnati, Ohio
Miami Valley Hospital
Dayton, Ohio
St. Elizabeth Youngstown Hospital
Youngstown, Ohio
St. John Health System Inc
Tulsa, Oklahoma
St. Mary Medical Center
Langhorne, Pennsylvania
Lankenau Medical Center
Wynnewood, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Texas Health Research and Education Institute
Fort Worth, Texas
Memorial Hermann Hospital - Texas Medical Center
Houston, Texas
Sentara RMH Medical Center
Harrisonburg, Virginia
Virginia Commonwealth University
Richmond, Virginia
Centro Privado de Cardiología
San Miguel de Tucumán, Argentina
Concord Repatriation General Hospital
Concord, New South Wales, Australia
St George Hospital
Kogarah, New South Wales, Australia
Royal North Shore Hospital
St Leonards, New South Wales, Australia
Westmead Hospital-Clinical Haematology Dept
Westmead, New South Wales, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
St. Vincents Hospital (MEL)
Fitzroy, Victoria, Australia
KH der Barmherzigen Schwestern Linz
Linz, Austria
Kepler Univ. Klinikum Linz
Linz, Austria
AKH - Medical University of Vienna
Vienna, Austria
Showing 40 of 176 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.